Antiretroviral Guidelines

US DHHS Guidelines with Australian commentary

Characteristics of the Fusion Inhibitor

Last Updated: October 25, 2018;

Last Reviewed: October 25, 2018

Generic Name
(Abbreviation)
Trade Name		 Formulation Dosing Recommendation Serum Half-Life Elimination Adverse Eventsa
Enfuvirtide 
(T-20)
Fuzeon		 Fuzeon:
  • Injectable; supplied as lyophilized powder.
  • Each vial contains 108 mg of T-20; reconstitute with 1.1mL of sterile water for injection for delivery of approximately 90 mg/1 mL.
  • Refer to prescribing information for storage instruction.
 Fuzeon:
  • 90 mg (1 mL) subcutaneously BID
 3.8 hours Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool
  • Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients
  • Increased incidence of bacterial pneumonia
  • HSR (<1% of patients): Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.
a Also see Table 15.

Key to Acronyms: BID = twice daily; HSR = hypersensitivity reaction; T-20 = enfuvirtide